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Enhanced Detection of Host Response Antibodies to Borrelia
burgdorferi Using Immuno-PCR
Micah D. Halpern, Sunny Jain, Mollie W. Jewett
Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida, USA
Lyme disease is the fastest-growing zoonotic disease in North America. Current methods for detection of Borrelia burgdorferi
infection are challenged by analysis subjectivity and standardization of antigen source. In the present study, we developed an
immuno-PCR (iPCR)-based approach employing recombinant in vivo-expressed B. burgdorferi antigens for objective detection
of a host immune response to B. burgdorferi infection. iPCR is a liquid-phase protein detection method that combines the sensi-
tivity of PCR with the specificity and versatility of immunoassay-based protocols. Use of magnetic beads coated with intact spi-
rochetes provided effective antigen presentation and allowed detection of host-generated antibodies in experimentally infected
mice at day 11 postinoculation, whereas host-generated antibodies were detected at day 14 by enzyme-linked immunosorbent
assay (ELISA) and day 21 by immunoblotting. Furthermore, magnetic beads coated with recombinant B. burgdorferi in vivo-
expressed antigen OspC or BmpA demonstrated positive detection of host-generated antibodies in mice at day 7 postinoculation
with markedly increased iPCR signals above the background, with the quantification cycle (Cq) value for each sample minus the
mean background Cq plus 3 standard deviations (Cq) being 4 to 10, whereas Cq was 2.5 for intact spirochete-coated beads.
iPCR demonstrated a strong correlation (Spearman rank correlation  0.895, P < 0.0001) with a commercial ELISA for detec-
tion of host antibodies in human Lyme disease patient sera using the B. burgdorferi VlsE C6 peptide. In addition, iPCR showed
potential applicability for direct detection of spirochetes in blood. The results presented here indicate that our iPCR assay has
the potential to provide an objective format that can be used for sensitive detection of multiple host response antibodies and
isotypes to B. burgdorferi infection.
Lyme disease is the leading vector-borne bacterial disease in theworld, with approximately 30,000 cases reported in the United
States alone each year (http://www.cdc.gov/lyme/). Lyme disease
has been characterized as the fastest-growing zoonotic disease in
North America. According to the Centers for Disease Control and
Prevention (CDC), the number of clinical cases of Lyme disease
has more than doubled over the past 10 years, making this emerg-
ing infectious disease a major public health concern (http://www
.cdc.gov/lyme/). Accurate diagnosis is currently the greatest chal-
lenge for the clinical management of Lyme disease. Misdiagnosis is
common, as the clinical manifestations of the disease are not
unique and detection of a Borrelia burgdorferi infection is difficult
and prone to misinterpretation (1, 2). Different approaches for
laboratory testing, such as microscopy, genomic DNA amplifica-
tion, and serology, have been examined, with currently accepted
laboratory diagnostics primarily relying on detection of a serolog-
ical response to B. burgdorferi antigens (1, 3, 4).
Current methods for detection of Lyme disease in a clinical
setting approved by the CDC entail a two-tiered approach using a
first-tier enzyme immunoassay (EIA) followed by a second-tier
immunoblot assay for both IgM and IgG B. burgdorferi-specific
antibodies using whole-cell B. burgdorferi lysates, recombinant
antigens, or various combinations, depending on the commercial
kit used (1). Although adequate, the approach suffers from certain
drawbacks, including the subjectivity of immunoblot analysis and
the lack of standardization of antigen source and lysate prepara-
tions. These challenges have resulted in discordant results between
test strategies for detection of host antibodies on the basis of the kit
used (5) largely due to lysate/antigen reagent variability (1). The
most effective approach appears to be the use of a combination of
recombinant antigens to replace whole-organism sonicates, as no
single antigen has been found to be sufficient for accurate diagno-
sis (1).
Other methods for detection of Lyme disease include live cul-
ture and approaches employing PCR. Live culture has shown lim-
ited success in a clinical setting, is time-consuming, and requires
complex media that have a limited commercial supply (1). PCR
appears to be the most promising method for direct detection of
spirochetes but has not been widely accepted for laboratory diag-
nosis due to low sensitivity in cerebrospinal fluid and blood and
the potential for false-positive results due to accidental laboratory
contamination of samples with small quantities of target DNA (6).
An improved approach would be to utilize the sensitivity of PCR
combined with an antigen-based detection system that is much
less susceptible to false-positive results.
Immuno-PCR (iPCR) was first introduced by Sano et al. in
1992 (7) and combines the amplification power of PCR with the
versatility of EIA, resulting in improved conventional antigen de-
tection sensitivity. Using iPCR, a typical 100- to 10,000-fold im-
provement over the detection limit of the EIA has been obtained
in almost all applications (8). iPCR has been used to detect viral
antigens (9), bacterial antigens (10), prions (11), and bacterial
toxins (12). There has also been a limited application of iPCR for
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antibody detection, such as the measurement of mumps virus-
specific immunoglobulin G in human serum (13).
The combination of an iPCR approach and recombinant B.
burgdorferi in vivo-expressed antigens has the potential to alleviate
a number of the issues posed by Lyme disease diagnostics. Recom-
binant antigens not only have the potential to standardize the
reagents used for Lyme disease diagnostics but also provide the
opportunity to combine antigens from multiple strains/species.
The sensitivity, ease of use, objective analysis, and multiplex capa-
bilities of iPCR (14) also make it an ideal platform for Lyme dis-
ease detection. Furthermore, iPCR has the ability to be translated
to an automated point-of-care diagnostic platform using micro-
fluidics (15) that may allow routine, high-throughput, and afford-
able diagnostic testing of patients for Lyme disease. The goal of
this research was to explore the initial application of iPCR using
recombinant antigens for either detection of host-generated anti-
bodies or direct detection of spirochetes in B. burgdorferi-infected
samples.
MATERIALS AND METHODS
Bacterial strains. B. burgdorferi clones B31 A3 (16) and B31 A34/
pBSV2G-loxP-flaBp-gfp (17) were used in these studies. Spirochetes were
grown in liquid Barbour-Stoenner-Kelly (BSK) II medium supplemented
with gelatin and 6% rabbit serum (18) and plated in solid BSK medium as
previously described (19). All spirochete cultures were grown at 35°C and
supplemented with 2.5% CO2. Gentamicin was used at 40 g/ml. Esche-
richia coli strains DH5 and BL21 (Novagen, Billerica, MA) were grown in
LB broth, on LB agar plates, or in Magic Media (Invitrogen, Carlsbad, CA)
containing 100 g/ml ampicillin.
Mouse infections. The University of Central Florida (UCF) is accred-
ited by the International Association for Assessment and Accreditation of
Laboratory Animal Care. Protocols for all animal experiments were pre-
pared according to the guidelines of the National Institutes of Health and
approved by UCF’s Institutional Animal Care and Use Committee. For
the serological detection experiments, the hair on the upper backs of three
mice (6- to 8-week-old C3H/HeN females; Harlan Laboratories, Inc.,
Dublin, VA) was removed by shaving, and the mice were needle inocu-
lated intradermally on the upper back with B. burgdorferi strain B31 A3 at
a dose of 1  105 spirochetes divided between two 50-l inoculations. The
number of spirochetes inoculated into mice was determined using a
Petroff-Hausser counting chamber and verified by CFU counts in solid
BSK medium. The total plasmid content of each inoculum was confirmed
to be as expected (20). Whole-blood samples were collected from the three
inoculated mice as well as one noninoculated mouse by submandibular
bleed preinoculation and at days 1, 3, 4, 7, 9, 11, 14, 16, 18, and 21 postin-
fection. The coagulated blood was spun at 4,000  g for 9 min to prepare
serum. For the spirochete detection experiments, six mice (6- to 8-week-
old C3H/HeN females; Harlan Laboratories, Inc., Dublin, VA) were inoc-
ulated intradermally with B. burgdorferi strain B31 A3 at a dose of 1  105
spirochetes. Approximately 50 l of blood was collected by submandib-
ular bleed from all mice prior to inoculation. Subsequently, to prevent
complications due to oversampling, approximately 50 l of blood/mouse
was collected every day from groups of two mice so that each group of two
mice was bled every 3 days over a time period of 14 days. All blood samples
(pre- and postinoculation) were supplemented with an equal volume of
0.5 M sodium EDTA to prevent coagulation.
Similar to plating of in vitro-grown B. burgdorferi, 50 l of blood from
each mouse was combined with BSK plating medium (19) supplemented
with a Borrelia antibiotic cocktail consisting of 20 l/ml phosphomycin
(MP Biomedicals, Santa Ana, CA), 50 l/ml rifampin (Fisher Scientific,
Waltham, MA), and 2.5 l/ml amphotericin B (Fisher Scientific, Wal-
tham, MA), all solubilized in 20% dimethyl sulfoxide. The mixture was
poured into sterile petri plates, allowed to solidify, and incubated as indi-
cated above for approximately 7 days, until B. burgdorferi colonies were
visible in the solid medium.
Immunoblotting and C6 peptide ELISA. Total B. burgdorferi lysate
for immunoblot analysis was prepared from a 500-ml culture of 1 
108/ml B. burgdorferi B31 A3. Spirochetes were harvested by centrifuga-
tion and washed two times in 30 ml phosphate-buffered saline (PBS; pH
7.4). Washed cells were resuspended in 30 ml PBS and disrupted by son-
ication on ice using a Misonix model S-4000 sonicator at 40% amplitude
for four repetitions of 20 s each. Total protein in the sonicate was normal-
ized to 1 mg/ml with PBS on the basis of the absorbance at 280 nm, and 75
g of protein was separated by 12.5% polyacrylamide gel electrophoresis.
Following protein transfer, nitrocellulose membranes were incubated for
1 h with pre- and postinoculation mouse serum diluted 1:200 in Tris-
buffered saline– 0.05% Tween (TBST; pH 7.6), washed twice with TBST,
incubated with horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG/IgM (Chemicon International, Billerica, MA) for 1 h, and
washed twice with TBST; and the signal was detected using a SuperSignal
West Pico chemiluminescent substrate kit (Thermo Scientific, Rockford,
IL). The C6 peptide B. burgdorferi enzyme-linked immunosorbent assay
(ELISA) was performed according to the manufacturer’s protocol (Im-
munetics, Boston, MA), with the exception of the use of HRP-conjugated
goat anti-mouse IgG/IgM secondary antibody (Chemicon International,
Billerica, MA) at a 1:5,000 dilution in place of the anti-human reporter
antibody provided with the kit when mouse sera were analyzed.
Cloning and expression of recombinant GST-tagged antigens. In-
frame glutathione S-transferase (GST) fusion proteins for OspC, BmpA,
and the VlsE C6 peptide were generated by PCR amplifying the corre-
sponding coding regions without the signal sequences from B. burgdorferi
genomic DNA using primer pairs P1 and P2 (OspC), P3 and P4 (BmpA),
or P5 and P6 (VlsE C6) engineered with a BamHI or SalI restriction site
(Table 1) and Phusion polymerase (New England BioLabs, Ipswich, MA).
PCR products were purified (Qiagen, Valencia, CA), digested with restric-
tion enzymes (New England BioLabs, Ipswich, MA), and cloned into
BamHI/SalI-digested pGEX-6P-1 (GE Healthcare, Piscataway, NJ) to
generate translational fusions with GST at the N terminus. Subsequent
clones were selected and sequence confirmed by dideoxy sequencing.
Hemagglutinin (HA; OspC) and c-Myc (BmpA) tags were included at the
C terminus for determination of protein purity by immunoblotting.
pGEX-6P-1 plasmids carrying ospC, bmpA, or vlsE c6 were transformed
into a BL21 strain of E. coli (Novagen, Billerica, MA). Protein expression
and purification were performed according to the procedures outlined in
the Bulk GST purification module (GE Health Sciences, Piscataway, NJ).
iPCR reagent preparation. iPCR assays were assembled in a two-sided
(sandwich) manner for both host antibody (Fig. 1A and B) and spirochete
capture (Fig. 1C). Whole-cell lysate used for immunoblot analysis (prep-
aration described above) and GST-fusion recombinant antigens were
used to coat magnetic beads for host antibody capture using a Dynabeads
antibody coupling kit (Invitrogen, Carlsbad, CA). Bead-coupling reac-
tions were performed overnight according to the manufacturer’s protocol
using 20 to 30 g antigen(s) per mg Dynabeads M-270 epoxy. The pri-
mary antibody used for spirochete capture consisted of protein A-purified
anti-B. burgdorferi polyclonal antibody raised in rabbits against whole-cell
preparations of B. burgdorferi clone B31 ATCC 35210 (Acris Antibodies,
San Diego, CA) and was coupled to magnetic beads as described above.
Protein-coated beads were stored at 4°C. The streptavidin-conjugated
reporter antibodies were prepared using a Lightning-Link streptavidin
conjugation kit (Innova Biosciences, Cambridge, United Kingdom) and
polyclonal anti-B. burgdorferi (Acris Antibodies, San Diego, CA), goat
anti-mouse IgM/IgG (Sigma-Aldrich, St. Louis, MO), goat anti-human
IgG (Invitrogen, Carlsbad, CA), or goat-anti-human IgM (Invitrogen,
Carlsbad, CA) antibody according to the manufacturer’s protocols using
an overnight incubation. Following conjugation, 10 l of streptavidin-
labeled antibody was diluted 1:50 in TBST, 100 nM single-stranded bio-
tin-labeled oligonucleotide template was added, and the mixture was ro-
tated at room temperature for 30 min for antibody-oligonucleotide
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conjugation. Oligonucleotide sequences T1 (IgG coupled) and T2 (IgM
coupled) used for tagging are listed in Table 1. The oligonucleotide-linked
streptavidin-conjugated antibody was then diluted to a 1:100 working
stock (final dilution, 1:5,000) and stored at 4°C.
iPCR assay. Following reagent preparation, 10 l of antigen- or anti-
body-coated magnetic beads was incubated in 500 l TBST for 30 min at
25°C on a rotator. Following preliminary washing, beads were resus-
pended in 500 l TBST and 5 l serum (mouse or human), 10 l spiro-
chetes was suspended in HN buffer (50 mM HEPES, 50 mM NaCl; pH 7.5)
or blood (1  108 to 1  104/ml B. burgdorferi B31 A3) or no serum/
spirochete was used (negative control), and the mixture was incubated at
25°C with rotation for 30 min. Beads were subsequently washed and re-
suspended in 300 l TBST with the addition of 100 l each of IgG and IgM
diluted (1:5,000) biotinylated oligonucleotide streptavidin-coupled re-
porter antibody (anti-mouse IgM/IgG, anti-human IgG, anti-human
IgM, or anti-B. burgdorferi), and the mixture was incubated at 25°C with
rotation for 30 min. Following assembly of the immune complex, beads
were washed three times with 900 l TBST, followed by magnetic bead
capture. Washed immune complex-coupled beads were resuspended in
20 l TBST for subsequent PCR amplification.
Signal amplification by real-time PCR. To amplify the signal of the
immune complex, real-time PCR was performed using an Applied Bio-
systems 7900 HT system (Life Technologies, Grand Island, NY) and IQ
Supermix (Bio-Rad, Hercules, CA) supplemented with synthetic primers
and probes T1F/T1R/T1P (IgG detection) or T2F/T2R/T2P (IgM detec-
tion) (Table 1). Duplicate reaction mixtures were prepared in 20-l vol-
umes containing 5 l of iPCR assay-processed beads as the template, 10 l
of 2 reaction mix, 0.2 M each primer, and 0.4 M fluorophore-labeled
probe. Cycle parameters included a preliminary denaturation (95°C, 20
s), followed by 40 cycles of denaturation (95°C, 1 s) and annealing/exten-
sion (60°C, 20 s). The fluorescent signal was collected at the 6-carboxy-
fluorescein (FAM) wavelength for IgG reactions and MAX (NHS ester;
Integrated DNA Technologies, Coralville, IA) wavelength for IgM reac-
tions. The quantification cycle (Cq) for each reaction was determined
using automatic baseline and threshold settings. The average and standard
deviation for uninfected/healthy samples were used to determine the
background level of amplification, as is commonly observed for iPCR
protocols. Positive threshold values were established at three times the
standard deviation for background levels.
Human sera. Retrospective, deidentified human Lyme disease and
healthy control serum samples were kindly supplied by Martin Schriefer
(Centers for Disease Control and Prevention, Fort Collins, CO). Sera were
collected from 18 Lyme disease patients from regions where Lyme disease
is endemic upon the initial visit to a physician and 10 days after the initial
visit (n  36). According to CDC’s two-tiered serological analysis of the
samples, 5 of the patients were two-tiered analysis positive at both the
initial and follow-up time points, 3 of the patients were two-tiered analysis
negative at both time points, and 10 of the patients were two-tiered anal-
ysis negative at the initial visit but two-tiered analysis positive 10 days
later. Human control samples consisted of sera collected from healthy
blood donors living in areas where Lyme disease is not endemic (n  5).
Statistical analysis. Spearman rank correlation analyses were per-
formed using GraphPad Prism software, version 5.0.
TABLE 1 iPCR DNA oligonucleotide sequences used in this study
Oligonucleotide
no. Oligonucleotide identification Sequence (5=–3=)a
T1 Template 1 (IgG coupled) Biotin-AGCCTCAGACCAAGCCAGACAACTGCCTCGTGACGTTGCTGCCCCTACCA
ACGTACCCCTACGAGTCC
T1F Template 1 forward AGCCTCAGACCAAGCCAGAC
T1R Template 1 reverse GGACTCGTAGGGGTACGTTGG
T1P Template 1 probe FAM-ACTGCCTCGTGACGTTGCTGCCCCT-BHQ1
T2 Template 2 (IgM coupled) Biotin-AGGAGGAGGGTCAAGTCACCAACGCTGCTCCAGGCCATCGTGCTGATCT
GGACCCTGGATCGAGTGA
T2F Template 2 forward AGGAGGAGGGTCAAGTCACC
T2R Template 2 reverse TCACTCGATCCAGGGTCCAG
T2P Template 2 probe MAX-ACGCTGCTCCAGGCCATCGTGCTGA-BHQ1
P1 OspC partial HA forward cgggatcccatatgTGTAATAATTCAGGGAAAGATGG
P2 OspC HA reverse acgcgtcgacTTAcgcataatccggcacatcatacggataAGGTTTTTTTGGACTTTCTGC
P3 BmpA partial myc forward cgggatcccatATGTGTAGTGGTAAAGGTAGTCTTG
P4 BmpA myc reverse acgcgtcgacTTAcagatcttcttcagaaataagtttttgttcAATAAATTCTTTAAGAAACTTCTCATAAC
P5 C6 Bb forward cgggatcccatATGAAGAAGGATGATCAGATTG
P6 C6 Bb reverse acgcgtcgacTTACTTCACAGCAAACTTTCCATC
a Lowercase letters indicate nontemplate sequence used for addition of terminal restriction sites and/or epitope tags. BHQ1, black hole quencher 1.
FIG 1 Schematic representation of iPCR assay for detection of Lyme disease
biomarkers. Intact spirochete (A) or recombinant protein antigen coupled to
magnetic beads (B) was used to capture B. burgdorferi-specific host-generated
antibodies. A biotinylated DNA oligonucleotide reporter molecule coupled to
a streptavidin-conjugated reporter antibody was amplified by qPCR for detec-
tion and quantification. (C) Anti-B. burgdorferi antibody coupled to magnetic
beads was used for spirochete capture, with detection accomplished by qPCR
amplification of the DNA oligonucleotide-coupled reporter antibody, similar
to detection of host antibody.
Halpern et al.
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iPCR using intact spirochetes provided earlier detection of host
response than immunoblotting and C6 ELISA in a murine
model. The general approach for detection of a host antibody
immune response by immunoassay is to use sonicated or other-
wise disrupted organisms to generate protein antigens for anti-
body capture and subsequent detection. However, we hypothe-
sized that this approach may have limited success for effectively
capturing anti-B. burgdorferi antibodies in experimentally in-
fected mouse serum, as the majority of the B. burgdorferi proteins
in the total cell lysate are not likely to be immunogenic. Although
B. burgdorferi lysate is known to harbor antigenic proteins recog-
nized by mouse and human immune sera, these proteins represent
a small percentage of the total proteins in the lysate and therefore
may not provide an improved sensitivity of detection of an im-
mune response to B. burgdorferi infection. In an effort to develop
a sensitive, objective method for detection of host antibodies
against B. burgdorferi antigens, magnetic beads were coated with a
polyclonal anti-B. burgdorferi antibody in order to capture forma-
lin-fixed intact spirochetes, resulting in the generation of mag-
netic beads coated with intact spirochetes (Fig. 2). We predicted
that this strategy would result in magnetic beads coated in an
enriched pool of spirochete antigenic outer surface proteins capa-
ble of interacting specifically with host antibodies produced in
response to a B. burgdorferi infection. The sensitivity of iPCR using
intact spirochetes to capture host antibodies was compared to the
sensitivities of preexisting diagnostic methods, including a com-
mercial C6 ELISA and immunoblotting, using an in vivo murine
model. iPCR resulted in the earliest objective detection of a posi-
tive infection on day 11 postinoculation (Fig. 3A). In comparison,
C6 ELISA and immunoblotting exhibited positive detection of
anti-B. burgdorferi antibodies at day 14 and day 21 postinocula-
tion, respectively (Fig. 3B and C). The approximate molecular
masses of the immunodominant proteins detected on the immu-
noblot included 18 kDa, 23 kDa, 33 kDa, 39 kDa, and 66 kDa,
which are consistent with the sizes of the bands typically present
on a Lyme disease diagnostic immunoblot (21, 22). Uninfected
mouse serum was negative by all three methods at all time points
tested (Fig. 3).
iPCR using recombinant GST-OspC and GST-BmpA pro-
vided improved sensitivity of detection of murine host antibod-
ies. Although beads coated with intact in vitro-grown spirochetes
provided early detection of anti-B. burgdorferi antibodies com-
pared to the time to detection by C6 ELISA and immunoblotting
(Fig. 3), we hypothesized that the use of specific recombinant
antigens known to be actively expressed during murine infection
could potentially result in a more sensitive approach. Known B.
burgdorferi in vivo-expressed antigens OspC and BmpA (1) were
produced and purified as recombinant N-terminal GST-tagged
FIG 2 B. burgdorferi captured on magnetic beads provides a reagent for host
antibody detection by iPCR. Phase-contrast microscopy and fluorescence mi-
croscopy at 510 nm (GFP [green fluorescent protein]) and 400 magnifica-
tion (400) were used to determine capture of formalin-fixed B. burgdorferi
expressing green fluorescent protein on beads coated with anti-B. burgdorferi
(Bb) polyclonal antibodies (top) or uncoated beads (bottom).
FIG 3 iPCR demonstrated earlier detection of host response antibodies in B.
burgdorferi-infected mice than C6 ELISA and immunoblotting. Mouse sera
were collected prior to inoculation (Pre), on specific days after intradermal
inoculation with 1  105 B. burgdorferi B31 A3 spirochetes (left), or from
uninfected mice (right) over the course of 21 days. (A) Undiluted sera were
analyzed for detection of B. burgdorferi IgG antibodies using iPCR. A closed-
system, real-time PCR of the DNA reporter molecule was performed using a
TaqMan-based fluorescent probe assay. The mean Cq background signal, de-
termined using uninfected sera plus 3 standard deviations, was designated the
call threshold for a positive detection event and indicated here as a Cq of 0.
Data are shown as the Cq value for each sample minus the mean background Cq
plus 3 standard deviations (Cq). Each data point represents the average of
three mice, and the standard deviation between samples is shown. (B) C6
ELISA (Immunetics, Inc., Boston, MA) was performed according to the man-
ufacturer’s instructions, with the exception that the secondary antibody was
peroxidase-conjugated goat anti-mouse IgM/IgG (1:5,000). The threshold ab-
sorbance for the test is indicated (horizontal broken line). Each point repre-
sents the average of three mice, and the standard deviation between samples is
shown. (C) Total B. burgdorferi sonicate was separated by SDS-PAGE and
analyzed by IgM/IgG immunoblotting using immune and preimmune mouse
sera diluted 1:200. The positions of the protein standards depict molecular
masses (in kilodaltons). Data are representative of three mice analyzed.
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fusion proteins in E. coli. Magnetic beads coated with either re-
combinant protein were used to capture host antibodies generated
against OspC or BmpA, respectively, and IgM and IgG antibodies
against each protein were individually quantitated using our iPCR
assay. The use of GST-OspC-coated beads resulted in a marked
increase in detection of host antibodies starting at day 7 postinoc-
ulation for both IgG and IgM (Fig. 4A), with a gradual decrease in
the IgM signal back to baseline by day 21 and a minimal decrease
in the IgG signal to the same time point. GST-OspC-coated beads
provided a dramatic increase in the level of IgG detection (Cq value
for each sample minus the mean background Cq plus 3 standard
deviations [Cq]  10) compared to the level of iPCR detection of
host antibodies using intact spirochete-coated beads (Cq  2.5).
GST-BmpA-coated beads provided robust positive detection of
IgG antibodies beginning at day 9, followed by a minimal decrease
in the detection signal out to day 21 (Fig. 4B). IgM antibodies
directed against BmpA demonstrated a slight increase in signal
over the 21-day time course of infection but were not detected at
levels significantly above background levels, suggesting that
BmpA does not elicit a serodiagnostic IgM response. Together
these data suggest that the use of magnetic beads coated with spe-
cific recombinant B. burgdorferi in vivo-expressed antigens results
in robust iPCR detection of a humoral response in mice experi-
mentally infected with B. burgdorferi and that development of an
iPCR assay that quantitates the host response to multiple B. burg-
dorferi antigens may result in an improved diagnostic method.
iPCR demonstrated a strong correlation with a commercial
ELISA for detection of host antibodies in human serum using
the VlsE C6 peptide. As recommended by the CDC, the first step
of two-tier testing for Lyme disease is the use of a sensitive enzyme
immunoassay. Although a number of commercial kits exist for
testing, the C6 peptide of the VlsE locus has been shown to be a
sensitive and effective predictor for follow-up testing by immuno-
blotting and is available as a commercial testing kit. In order to
directly compare the ability of our iPCR assay to detect human
antibodies produced against the VlsE C6 peptide with that of an
FDA-approved C6 antibody detection method, a panel of serum
samples from 18 individuals collected at both an initial visit to the
clinic and a 10-day follow-up appointment (n  36) along with
sera collected from 5 healthy patients from areas where Lyme dis-
ease is not endemic was analyzed by iPCR and the C6 Lyme disease
ELISA (Immunetics, Inc., Boston, MA). iPCR detection of C6-
specific host antibodies demonstrated a strong correlation with
detection by the commercial C6 ELISA (Spearman rank correla-
tion [rs]  0. 895, P  0.0001) (Fig. 5). The iPCR assay differed
from the C6 ELISA in that the iPCR assay provided a separate
measurement of C6 IgM and C6 IgG antibodies, whereas the C6
ELISA quantitated a combined value for both C6 IgM and C6 IgG
antibodies. Therefore, the iPCR result was considered positive if
C6 IgM and/or C6 IgG antibodies were detected at or above the
established call threshold. All 21 samples that demonstrated a pos-
itive result by the C6 ELISA were also positive according to the C6
iPCR (Fig. 5). Of the four serum samples determined to be equiv-
ocal by the C6 ELISA, three were found to be negative by C6 iPCR,
whereas one sample tested positive for IgM using this method.
Furthermore, of the 11 serum samples that tested negative by the
C6 ELISA, 5 resulted in positive detection of IgM by C6 iPCR. Of
note, all iPCR-positive samples in this group had Cq values of 1
or below. All serum samples collected from known healthy indi-
viduals tested negative by both the C6 ELISA and C6 iPCR. To-
gether these results suggest that iPCR may have an improved abil-
ity to detect host antibodies to the VlsE C6 peptide compared to
that of a current commercial method.
iPCR directly detected B. burgdorferi in blood. The demon-
strated power of iPCR to detect ultralow protein levels (8) suggests
that this method may be a promising tool for direct detection of B.
burgdorferi in clinical samples. iPCR was shown to be successful
for capture of live B. burgdorferi using magnetic beads coated with
polyclonal anti-B. burgdorferi antibodies (Fig. 2). This finding
suggested the potential for iPCR to directly quantitate spirochetes
from within patient samples. To test the sensitivity of iPCR detec-
tion of spirochetes, in vitro-grown B. burgdorferi was serially di-
luted in HN buffer (106 to 102 spirochetes). iPCR detection of
spirochetes demonstrated a robust dilution curve and a level of
detection of less than 1,000 organisms (Fig. 6A). Detection of in
vitro-grown B. burgdorferi spiked into whole uninfected mouse
blood resulted in a 10-fold lower limit of detection of 10,000 spi-
rochetes (data not shown), suggesting that components of the
blood may have an inhibitory effect on the function of the iPCR
assay. To correlate the sensitivity of iPCR detection of spirochetes
in blood with quantitation of the number of spirochetes present in
the blood of infected mice, cohorts of mice were infected with 1 
FIG 4 iPCR using recombinant antigens OspC and BmpA provided enhanced
sensitivity for detection of both IgG and IgM isotypes in a murine model of
infection. Magnetic beads coated with either purified recombinant GST-OspC
(A) or GST-BmpA (B) protein were used to capture host response antibodies
from preimmune (pre) or postimmune mouse sera collected over a time pe-
riod of 21 days. IgM- and IgG-specific reporter antibody-DNA conjugates
detected anti-B. burgdorferi antibodies captured by each set of antigen-coated
beads. The IgM and IgG response to each antigen was determined for each
mouse by multiplex quantitative PCR using distinct probes specific for the
IgM- and IgG-specific DNA reporter molecules. The mean Cq background
signal, determined using uninfected sera, plus 3 standard deviations was des-
ignated the call threshold for a positive detection event and indicated here as a
Cq of 0. Data are shown as the Cq value for each sample minus the mean
background Cq plus 3 standard deviations (Cq). Each data point represents
the average of two mice, and the standard deviation between samples is shown.
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105 B. burgdorferi B31 A3 spirochetes and blood samples were
collected every 24 h for a period of 14 days. The number of spiro-
chetes/ml of blood, as determined by CFU counts on solid me-
dium, was found to increase over the first week of infection and
reached a peak number of approximately 2,500 spirochetes/ml of
blood on day 8 postinoculation (Fig. 6B). The B. burgdorferi col-
onies that grew out of the infected blood within the solid BSK
medium demonstrated a morphology and a growth pattern simi-
lar to those that are typically observed for spirochete colonies de-
rived from in vitro-grown cultures (data not shown). Together,
these data suggest that although iPCR is a promising method for
direct detection of spirochetes in B. burgdorferi-infected samples,
the sensitivity of the method is currently below the required level
of detection.
DISCUSSION
There is a critical need for development of innovative methods for
improved diagnosis of Lyme disease. Because of its immunologi-
cal specificity, signal amplification power, and potential for high-
throughput automation, iPCR is a strong candidate for develop-
ment as a robust method to overcome the challenges of diagnosis
of Lyme disease. We have demonstrated the first application of
iPCR for detection of host antibodies against B. burgdorferi in both
a murine model and human serum.
iPCR using recombinant B. burgdorferi in vivo-expressed
antigens is a sensitive method for detection of host response
antibodies in infected mice. An iPCR assay that incorporated at-
tachment of intact spirochetes to magnetic beads provided sensi-
tivity approximately equivalent to the sensitivities of current di-
agnostic methods, including C6 ELISA and immunoblotting,
when tested in a murine model. However, it is well-known that B.
burgdorferi can alter its surface protein expression on the basis of
its environment (23–25). These data have led to the conclusion
that in vitro-grown spirochetes likely do not present amounts and
types of surface proteins equivalent to those that would be en-
countered by the host immune system in an active B. burgdorferi
FIG 6 iPCR has the potential to directly detect B. burgdorferi in infected
samples. (A) Live spirochetes were serially diluted in HN buffer (106 to 102
spirochetes) and tested in triplicate using iPCR to detect organism capture
using anti-B. burgdorferi antibody-coated magnetic beads. A call threshold was
assigned at greater than or equal to five times the standard deviation (Cq  30,
vertical broken line) above the mean background signal, as determined using
HN buffer alone (unspiked). PCR nontemplate controls (NTCs) included wa-
ter and TBST used during the iPCR protocol. Rn, normalized change in
fluorescence. (B) Six mice were prebled (Pre) and inoculated intradermally
with 1  105 B. burgdorferi strain B31 A3 spirochetes. Approximately 50 l of
blood/mouse was collected every day from groups of two mice so that each group
of two mice was bled every 3 days over a time period of 14 days. Blood collected
from each mouse was plated in solid medium using 50 l of blood and supple-
mented with a Borrelia antibiotic cocktail (see Materials and Methods for details),
and the number of CFU per ml of blood was determined. Data shown are the
average number of CFU/ml for the two mice sampled at each time point.
FIG 5 Recombinant antigen iPCR successfully quantified B. burgdorferi VlsE C6 peptide antibodies in human serum samples. Results are for 36 serum samples
from 18 Lyme disease patients collected upon the initial visit to a clinic and at a 10-day follow-up visit and 5 healthy controls using a multiplex iPCR protocol to
quantitate both IgM and IgG isotypes using recombinant B. burgdorferi VlsE C6 peptide-coated magnetic beads. A call threshold (Cq  0) was assigned at greater
than or equal to 3 standard deviations above the mean background signal determined using sera from healthy individuals. Serum samples were also tested using
a commercial C6 ELISA (Immunetics, Boston, MA) (diamonds), which was performed according to the manufacturer’s protocol, with a call threshold for an
absorbance (450 nm) of 1.1 used according to the manufacturer’s protocol. The C6 ELISA value represents combined measurement of C6 IgM and IgG
antibodies. The data for patients 1 to 36 are grouped into three categories: positive, equivocal (equiv), and negative according to the C6 ELISA values. Samples
H1 to H5 correspond to the sera collected from the healthy controls and are grouped accordingly (healthy). The calculated rs values were 0.734 (P  0.0001) for
C6 iPCR IgM versus C6 ELISA, 0.826 (P  0.0001) for C6 iPCR IgG versus C6 ELISA, and 0.895 (P  0.0001) for C6 iPCR IgM and/or IgG versus C6 ELISA.
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infection and suggest that the use of multiple in vivo-expressed
recombinant antigens may improve assay sensitivity (26).
B. burgdorferi has been shown to express a number of antigens
during an active infection, including OspC (27) and BmpA (28),
that can be utilized as recombinant antigens to detect host anti-
bodies against B. burgdorferi (21). We hypothesized that saturat-
ing the magnetic beads with recombinant in vivo-expressed anti-
genic proteins would provide more binding targets and hence a
higher sensitivity than intact spirochetes. This was evidenced by
the fact that active infection was detected on days 7 to 9 postinoc-
ulation using recombinant antigen-coated beads but on day 11
postinoculation using intact spirochete-coated beads and the fact
that the signal above the background was stronger with recombi-
nant antigen-coated beads, with Cq values being 4 to 10 and 2.5,
respectively. This approach also provides the opportunity to uti-
lize multiple specific antigens in either a combined or an individ-
ual assay that can be objectively quantified by quantitative PCR
(qPCR).
Recombinant antigen iPCR successfully quantified B. burg-
dorferi VlsE C6 peptide antibodies in human serum samples.
The immunodominant C6 peptide domain of the VlsE protein has
proven successful as a diagnostic antigen (29) and has become a
popular choice for first-tier testing prior to follow-up immuno-
blot testing (30). An iPCR assay employing a recombinant C6
peptide was developed and compared to an existing commercial
kit that uses the same antigen. iPCR detection of C6 antibodies in
human serum demonstrated a strong correlation with detection
by the commercial C6 Lyme disease ELISA. The C6 ELISA results
in a combined score for detection of both IgG and IgM isotypes.
To provide an additional level of discrimination, the iPCR proto-
col separately quantitates IgG and IgM antibodies using distinct
qPCR template tags and fluorophores, resulting in an individual
IgG and IgM iPCR score for each serum sample. All C6 ELISA-
positive serum samples were found to be positive for IgG and/or
IgM C6 antibodies by iPCR. The added ability of the iPCR assay to
differentially quantitate antibody isotypes for a specific antigen of
interest in a single sample may provide important information
regarding the disease stage at the time of testing, as IgM is typically
produced early in infection, with IgG being produced later and for
longer durations (21, 31).
Of the serum samples that were found to be equivocal or neg-
ative by C6 ELISA, a subset of samples in each category was found
to be positive by the C6 iPCR assay. These results imply that the
iPCR assay may have an increased sensitivity of detection over the
C6 ELISA; however, further analysis of a larger panel of serum
samples is required to fully support this finding. Serum samples
from healthy individuals with no known exposure to B. burgdor-
feri tested negative by both C6 ELISA and iPCR, suggesting equiv-
alent specificities for the two methods. However, considering the
small sample size (n  5), additional samples need to be tested to
confirm this result.
iPCR has the potential for direct detection of spirochetes in
infected samples. In an effort to test the applicability of iPCR for
direct detection of spirochetes within a sample, it was determined
that 1,000 spirochetes were needed in buffer and 10,000 organisms
were needed in blood. In the murine model used for development
of the protocol, the maximum spirochete load in blood was mea-
sured to be approximately 2,500 spirochetes/ml. Therefore, the
current protocol is unable to directly detect spirochetes during an
active murine infection. It has been estimated that the average
number of cultivable B. burgdorferi cells per ml of whole blood in
humans is approximately 0.1 spirochete per ml, and therefore,
reisolation of spirochetes from blood has been demonstrated to
have limited efficacy when using small volumes of blood (32).
Hence, an alternative approach has been proposed to sample
blood cultures and test by qPCR for increasing amounts of spiro-
chete DNA (33). While an enrichment step is practical, the use of
qPCR has the potential to introduce false-positive results from
contaminating B. burgdorferi template DNA in the laboratory and
typically requires additional protocol steps for nucleic acid puri-
fication. iPCR, which herein has demonstrated successful detec-
tion of spirochetes directly from whole blood and is much less
prone to the same contamination issues, as the PCR template is
unrelated to B. burgdorferi and human DNA, could effectively be
used to make a more rapid diagnosis from B. burgdorferi-infected
blood cultures. Future work will focus on improving the limit of
iPCR direct detection of spirochetes in blood to achieve a detec-
tion sensitivity of 1 to 10 organisms, as has been demonstrated for
other microbial pathogens (10, 34–36). Furthermore, as B. burg-
dorferi is transiently present in the blood of infected patients, the
iPCR method may also be adapted for direct detection of spiro-
chetes in synovial fluid and/or cerebrospinal fluid. Direct detec-
tion of spirochetes in patient samples is not anticipated to serve as
the sole method for diagnosis of Lyme disease; rather, it is antici-
pated to serve in conjunction with the sensitive and specific detec-
tion of B. burgdorferi antibodies.
Contributions of an iPCR-based approach using recombi-
nant antigens to future automated Lyme disease diagnostics.
The field of Lyme disease diagnostics is challenged by two main
issues: a lack of consistent reagents and the need for a more sim-
plified objective form of testing (1). There are currently multiple
commercial assays that use a range of antigen types, from single
recombinant antigens to multiple antigens to whole sonicated or-
ganisms. One principal focus for the field has been on the use of
purified, recombinant, or synthetic peptides as the source of anti-
gens in immunoassays (1). Unfortunately, no single antigen has
demonstrated sufficient sensitivity and specificity to warrant re-
placing two-tier testing (1). Protein expression differences among
species and the temporal appearance of relevant antibodies to dif-
ferent antigens at various stages of Lyme disease make the choice
of a single antigen a difficult task and make the combined use of
antigens an attractive alternative (1). The results presented here
suggest that iPCR combined with the use of recombinant B. burg-
dorferi in vivo-expressed antigens has the potential to provide im-
proved sensitivity of detection in an objective format that can be
used to detect multiple host response antibodies and isotypes.
Moreover, future translation of this method to an automated
point-of-care platform will allow objective routine testing of
Lyme disease patients.
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